⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Official Title: An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Study ID: NCT02592707

Study Description

Brief Summary: The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.

Detailed Description:

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas, United States

Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory, East Melbourne, , Australia

Ramsay Hollywood Private Hospital, Department of Nuclear Medicine, Perth, , Australia

University Hospital Vienna, Department of Nuclear Medicine, Vienna, , Austria

CHU de Quebec - Universite Laval Research Center, Department of Radiology and Nuclear Medicine, Québec, , Canada

University Hospital Aarhus, Department of Hepatology and Gastroenterology, Aarhus, , Denmark

CHU de Nantes, Hotel Dieu, Service de Medecine Nucleaire, Nantes, , France

University Hospital Basel, Department of Nuclear Medicine, Basel, , Switzerland

Royal Free Hospital, Department of Nuclear Medicine, London, , United Kingdom

Contact Details

Name: Ipsen Medical Director

Affiliation: Ipsen

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: